These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 31276688)

  • 41. Ghrelin O-acyltransferase (GOAT) is expressed in prostate cancer tissues and cell lines and expression is differentially regulated in vitro by ghrelin.
    Seim I; Jeffery PL; de Amorim L; Walpole CM; Fung J; Whiteside EJ; Lourie R; Herington AC; Chopin LK
    Reprod Biol Endocrinol; 2013 Jul; 11():70. PubMed ID: 23879975
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Identification of endonuclease domain-containing 1 as a novel tumor suppressor in prostate cancer.
    Qiu J; Peng S; Si-Tu J; Hu C; Huang W; Mao Y; Qiu W; Li K; Wang D
    BMC Cancer; 2017 May; 17(1):360. PubMed ID: 28532481
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Hypermethylation of Cyclin D2 is associated with loss of mRNA expression and tumor development in prostate cancer.
    Henrique R; Costa VL; Cerveira N; Carvalho AL; Hoque MO; Ribeiro FR; Oliveira J; Teixeira MR; Sidransky D; Jerónimo C
    J Mol Med (Berl); 2006 Nov; 84(11):911-8. PubMed ID: 17016690
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Expressions of E-cadherin and beta-catenin in LNCaP and ARCaP cell lines and their significance].
    Jiang YG; Zhao JH; Luo Y; He DL; Li N; Cui XH; Peng T
    Zhonghua Nan Ke Xue; 2009 Oct; 15(10):867-71. PubMed ID: 20112731
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Hypoexpression and epigenetic regulation of candidate tumor suppressor gene CADM-2 in human prostate cancer.
    Chang G; Xu S; Dhir R; Chandran U; O'Keefe DS; Greenberg NM; Gingrich JR
    Clin Cancer Res; 2010 Nov; 16(22):5390-401. PubMed ID: 21062931
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Deregulation of FOXO3A during prostate cancer progression.
    Shukla S; Shukla M; Maclennan GT; Fu P; Gupta S
    Int J Oncol; 2009 Jun; 34(6):1613-20. PubMed ID: 19424579
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Dickkopf-related protein 3 promotes pathogenic stromal remodeling in benign prostatic hyperplasia and prostate cancer.
    Zenzmaier C; Sampson N; Plas E; Berger P
    Prostate; 2013 Sep; 73(13):1441-52. PubMed ID: 23765731
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Expression of the VEGF-receptor Flt-1 in benign, premalignant and malignant prostate tissues.
    Hahn D; Simak R; Steiner GE; Handisurya A; Susani M; Marberger M
    J Urol; 2000 Aug; 164(2):506-10. PubMed ID: 10893635
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The miR-218/GAB2 axis regulates proliferation, invasion and EMT via the PI3K/AKT/GSK-3β pathway in prostate cancer.
    Tian J; Zhang H; Mu L; Wang M; Li X; Zhang X; Xie E; Ma M; Wu D; Du Y
    Exp Cell Res; 2020 Sep; 394(1):112128. PubMed ID: 32522441
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Regulation of androgen receptor transactivity and mTOR-S6 kinase pathway by Rheb in prostate cancer cell proliferation.
    Kobayashi T; Shimizu Y; Terada N; Yamasaki T; Nakamura E; Toda Y; Nishiyama H; Kamoto T; Ogawa O; Inoue T
    Prostate; 2010 Jun; 70(8):866-74. PubMed ID: 20127734
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Differential immunohistochemical expression of CD44s, E-cadherin and β-catenin among hyperplastic and neoplastic lesions of the prostate gland.
    Lazari P; Poulias H; Gakiopoulou H; Thomopoulou GH; Barbatis C; Lazaris AC
    Urol Int; 2013; 90(1):109-16. PubMed ID: 23220849
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Snail promotes cell migration through PI3K/AKT-dependent Rac1 activation as well as PI3K/AKT-independent pathways during prostate cancer progression.
    Henderson V; Smith B; Burton LJ; Randle D; Morris M; Odero-Marah VA
    Cell Adh Migr; 2015; 9(4):255-64. PubMed ID: 26207671
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Down-regulation of protein kinase, DNA-activated, catalytic polypeptide attenuates tumor progression and is an independent prognostic predictor of survival in prostate cancer.
    Zhang X; Wang Y; Ning Y
    Urol Oncol; 2017 Mar; 35(3):111.e15-111.e23. PubMed ID: 27856181
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Aberrant expression of DeltaNp73 in benign and malignant tumours of the prostate: correlation with Gleason score.
    Guan M; Chen Y
    J Clin Pathol; 2005 Nov; 58(11):1175-9. PubMed ID: 16254107
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Activation of PI3K-Akt signaling pathway promotes prostate cancer cell invasion.
    Shukla S; Maclennan GT; Hartman DJ; Fu P; Resnick MI; Gupta S
    Int J Cancer; 2007 Oct; 121(7):1424-32. PubMed ID: 17551921
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Signal transducer and activator of transcription-6 (STAT6) is a constitutively expressed survival factor in human prostate cancer.
    Das S; Roth CP; Wasson LM; Vishwanatha JK
    Prostate; 2007 Oct; 67(14):1550-64. PubMed ID: 17705178
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Proton pump inhibitors promote the growth of androgen-sensitive prostate cancer cells through ErbB2, ERK1/2, PI3K/Akt, GSK-3β signaling and inhibition of cellular prostatic acid phosphatase.
    Gesmundo I; Di Blasio L; Banfi D; Villanova T; Fanciulli A; Favaro E; Gamba G; Musuraca C; Rapa I; Volante M; Munegato S; Papotti M; Gontero P; Primo L; Ghigo E; Granata R
    Cancer Lett; 2019 May; 449():252-262. PubMed ID: 30790678
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Epithelial cell adhesion molecule (EpCAM) is associated with prostate cancer metastasis and chemo/radioresistance via the PI3K/Akt/mTOR signaling pathway.
    Ni J; Cozzi P; Hao J; Beretov J; Chang L; Duan W; Shigdar S; Delprado W; Graham P; Bucci J; Kearsley J; Li Y
    Int J Biochem Cell Biol; 2013 Dec; 45(12):2736-48. PubMed ID: 24076216
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Signal transduction pathways in androgen-dependent and -independent prostate cancer cell proliferation.
    Ghosh PM; Malik SN; Bedolla RG; Wang Y; Mikhailova M; Prihoda TJ; Troyer DA; Kreisberg JI
    Endocr Relat Cancer; 2005 Mar; 12(1):119-34. PubMed ID: 15788644
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Testis specific Y-like 5: gene expression, methylation and implications for drug sensitivity in prostate carcinoma.
    Kumar SR; Bryan JN; Esebua M; Amos-Landgraf J; May TJ
    BMC Cancer; 2017 Feb; 17(1):158. PubMed ID: 28235398
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.